Satoshi Mishima Selected Research

royal jelly

1/2011	Royal jelly facilitates restoration of the cognitive ability in trimethyltin-intoxicated mice.
3/2010	AMP N(1)-oxide, a unique compound of royal jelly, induces neurite outgrowth from PC12 cells via signaling by protein kinase A independent of that by mitogen-activated protein kinase.
12/2007	AMP N1-oxide potentiates astrogenesis by cultured neural stem/progenitor cells through STAT3 activation.
6/2007	Royal jelly-induced neurite outgrowth from rat pheochromocytoma PC12 cells requires integrin signal independent of activation of extracellular signal-regulated kinases.
4/2006	Identification of AMP N1-oxide in royal jelly as a component neurotrophic toward cultured rat pheochromocytoma PC12 cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Satoshi Mishima Research Topics

Disease

6	Neoplasms (Cancer) 04/2010 - 07/2003
4	Pheochromocytoma 03/2010 - 04/2006
3	Ganglion Cysts (Ganglion) 10/2009 - 03/2006
2	Myeloid Leukemia (Leukemia, Myelocytic) 10/2005 - 05/2005
2	Hypertension (High Blood Pressure) 10/2005 - 02/2004
2	Sarcoma (Soft Tissue Sarcoma) 06/2005 - 09/2003
1	Cognitive Dysfunction 01/2011
1	Hypersensitivity (Allergy) 09/2010
1	Leukemia 09/2010
1	Ischemic Stroke 05/2010
1	Retinal Neovascularization 04/2010
1	Pathologic Neovascularization 12/2009
1	Diabetic Retinopathy (Retinopathy, Diabetic) 11/2009
1	Hypertrophy 09/2008
1	Carcinoma (Carcinomatosis) 10/2007
1	Breast Neoplasms (Breast Cancer) 10/2007
1	Neoplasm Metastasis (Metastasis) 10/2007
1	Hypotension (Low Blood Pressure) 10/2005
1	Urticaria (Hives) 05/2005
1	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/2005
1	Brain Infarction 01/2005
1	Brain Ischemia (Cerebral Ischemia) 01/2005
1	Leukopenia 07/2004
1	Body Weight (Weight, Body) 09/2003

Drug/Important Bio-Agent (IBA)

10	Propolis (Bee Bread)IBA 09/2010 - 07/2003
5	royal jellyIBA 01/2011 - 04/2006
4	AMP N1-oxideIBA 03/2010 - 04/2006
3	DrupaninIBA 01/2007 - 07/2003
3	baccharinIBA 01/2007 - 07/2003
2	ResveratrolIBA 05/2010 - 10/2007
2	Oxygen (Dioxygen)IBA 04/2010 - 10/2009
2	Adenosine A2A Receptor (Adenosine A2A Receptors)IBA 03/2010 - 06/2007
2	Adenosine Monophosphate (AMP)IBA 03/2010 - 12/2007
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2009 - 11/2009
2	Ethanol (Ethyl Alcohol)IBA 10/2005 - 05/2005
1	IgE Receptors (Fc epsilon RI)IBA 09/2010
1	beta-N-AcetylhexosaminidasesIBA 09/2010
1	PPAR alphaIBA 05/2010
1	Angiogenesis Inducing Agents (Angiogenesis Factor)IBA 12/2009
1	Glucose (Dextrose)FDA LinkGeneric 10/2009
1	Neuroprotective AgentsIBA 10/2009
1	Phenobarbital (Luminal)FDA Link 09/2008
1	vaticanol CIBA 10/2007
1	IntegrinsIBA 06/2007
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 06/2007
1	3,4-di-O-caffeoylquinic acidIBA 01/2007
1	p-coumaric acidIBA 01/2007
1	Glutamic Acid (Glutamate)FDA Link 01/2007
1	Chlorogenic AcidIBA 01/2007
1	Glutathione (Reduced Glutathione)IBA 01/2007
1	buthionineIBA 01/2007
1	3,5-dicaffeoylquinic acidIBA 01/2007
1	artepillin CIBA 01/2007
1	Cystine (L-Cystine)IBA 01/2007
1	Antihypertensive Agents (Antihypertensives)IBA 10/2005
1	AcidsIBA 10/2005
1	cinnamic acidIBA 06/2005
1	AntioxidantsIBA 07/2004
1	Peptides (Polypeptides)IBA 02/2004
1	StilbenesIBA 09/2003

Therapy/Procedure

1	Subcutaneous Injections 09/2008
1	Therapeutics 10/2007
1	Oral Administration 09/2003